Should oncologists be aware in their clinical practice of KRAS molecular analysis?

J Clin Oncol. 2011 Mar 10;29(8):e206-7; author reply e208-9. doi: 10.1200/JCO.2010.32.7700. Epub 2011 Jan 24.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Attitude of Health Personnel
  • Awareness
  • Codon
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / secondary
  • DNA Mutational Analysis*
  • ErbB Receptors / antagonists & inhibitors
  • Genetic Testing / methods*
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Molecular Targeted Therapy
  • Mutation*
  • Patient Selection
  • Polymerase Chain Reaction
  • Precision Medicine*
  • Predictive Value of Tests
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • Retrospective Studies
  • ras Proteins / genetics*

Substances

  • Antineoplastic Agents
  • Codon
  • KRAS protein, human
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins